Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced that it will host a key opinion leader (KOL) webinar series featuring globally recognized experts in ophthalmology. The webinar series will be held in two parts and made available on Eyexora’s investors page. Details below:
Part 1: Advancing Sustained, Interventional Office-Based Therapies for Ocular Surface Disease
The webinar will feature a panel of leading ophthalmology KOLs discussing sustained, interventional office-based approaches to the treatment of ocular surface disease:
- Richard L. Lindstrom, M.D. (Unifeye Vision Partners, Minnesota)
- Prof. Jodhbir H. Mehta, MBBS, FRCOphth, FRCS(Ed), FAMS, PhD (Singapore National Eye Centre/Duke-NUS Medical School)
- Ehsan Sadri, M.D. (Visionary Eye Institute, California)
Part 2: Subretinal Fibrosis in Retinal Vascular Diseases
The webinar will feature a panel of leading ophthalmology and retina KOLs discussing subretinal fibrosis in retinal vascular diseases:
- David Boyer, M.D. (Retina-Vitreous Associates Medical Group, California)
- Prof. Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI (Singapore National Eye Centre)
- Diana Do, M.D. (Stanford Medicine, California)
- Arshad Khanani, M.D., MA (Sierra Eye Institute, Nevada)
For more information on Eyexora and to view the webinar series, please visit Eyexora’s website at https://eyexora.com/investors/.
About Eyexora
Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact.
Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company and product launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter. For more information, visit www.eyexora.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260915268172/en/
Media gallery
